We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mettler-Toledo's Q3 Earnings on Deck: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Mettler-Toledo will report Q3 results on Nov. 5, with revenues estimated to rise 3.9% to $1.07 billion.
Mettler-Toledo's EPS is projected to grow 8.6% to $12.11, supported by Spinnaker and improving markets.
Lab, Industrial and emerging-market growth, automation demand and acquisitions may boost MTD's results.
Mettler-Toledo International Inc. (MTD - Free Report) is set to report third-quarter 2026 results on Nov. 5, after the market close.
This renowned global supplier of precision instruments and services posted adjusted earnings per share (EPS) of $11.46 in the last reported quarter, surpassing the Zacks Consensus Estimate by 6.3%. Mettler-Toledo beat on earnings in each of the trailing four quarters, delivering an average surprise of 4.60%.
Q3 Estimates for MTD
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $1.07 billion, indicating a 3.9% increase from the year-ago reported figure.
The Zacks Consensus Estimate for third-quarter EPS is pegged at $12.11, suggesting an upside of 8.6% year over year. The estimate has remained constant in the past 60 days.
Let’s briefly review how the company has performed ahead of the announcement.
Key Trends Influencing MTD’s Q3 Performance
In the third quarter, Mettler-Toledo likely benefited from improving market conditions, especially in China and emerging markets. The company was encouraged by this trend in the previous quarter and also raised its projections for full-year 2026 local currency sales and adjusted EPS growth. MTD’s limited exposure to the volatile Middle East, the absence of any significant change in customer behavior and management’s confidence in executing its growth and productivity initiatives may have also supported the outlook.
Alongside this, Mettler-Toledo’s focus on capturing growth opportunities through its Spinnaker sales and marketing excellence program, as well as customer investment trends in automation, digitalization and onshoring, may have supported performance. Several recent acquisitions may have also contributed.
Mettler-Toledo International, Inc. Price and EPS Surprise
Across product categories, Lab results likely benefited from improving trends across the biopharma customer base, along with robust performance in Process Analytics and bioproduction. Laboratory balances and analytical instruments may have gained from several innovations introduced in recent years, the LabX software platform and growing demand from segments such as semiconductors, advanced materials and batteries.
Industrial results in the third quarter of 2026 are likely to be driven by demand for solutions that enable automation. Strength across markets such as biopharma, food manufacturing, semiconductors and new energy may have continued. Product Inspection sales may have picked up following modest organic growth in the previous quarter, which was due to the timing of customer projects. Food Retail may have also made a favorable contribution to overall sales.
From a geographic standpoint, Mettler-Toledo likely continued to see momentum in most Lab product categories, Core Industrial Automation Solutions and Product Inspection in the Americas. Europe may have recorded growth across most of the business, with Core Industrial and Food Retail showing particular strength. Asia/Rest of the World likely continued to deliver broad-based growth across the portfolio and most major markets.
MTD’s markets outside China likely continued to deliver strong growth. Emerging markets, including India, Southeast Asia, Eastern Europe and Latin America, may have remained important contributors, supported by growth opportunities and investments in nearshoring. These regions have been a key part of the company’s long-term growth strategy and are expected to offer further opportunities as they mature.
In Mexico, the company continued to develop local assembly and manufacturing capabilities to address local market needs and enhance its competitive position. Combined, all these developments are expected to have positively impacted Mettler-Toledo’s third-quarter 2026 results.
What Our Model Unveils for MTD
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Mettler-Toledo has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #2 at present. The company is slated to release first-quarter fiscal 2027 results on Nov. 5.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.66% and a Zacks Rank #2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Nov. 4.
COR’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 0.76%. The Zacks Consensus Estimate for fourth-quarter EPS implies a jump of 18.5% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Mettler-Toledo's Q3 Earnings on Deck: What's in Store for the Stock?
Key Takeaways
Mettler-Toledo International Inc. (MTD - Free Report) is set to report third-quarter 2026 results on Nov. 5, after the market close.
This renowned global supplier of precision instruments and services posted adjusted earnings per share (EPS) of $11.46 in the last reported quarter, surpassing the Zacks Consensus Estimate by 6.3%. Mettler-Toledo beat on earnings in each of the trailing four quarters, delivering an average surprise of 4.60%.
Q3 Estimates for MTD
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $1.07 billion, indicating a 3.9% increase from the year-ago reported figure.
The Zacks Consensus Estimate for third-quarter EPS is pegged at $12.11, suggesting an upside of 8.6% year over year. The estimate has remained constant in the past 60 days.
Let’s briefly review how the company has performed ahead of the announcement.
Key Trends Influencing MTD’s Q3 Performance
In the third quarter, Mettler-Toledo likely benefited from improving market conditions, especially in China and emerging markets. The company was encouraged by this trend in the previous quarter and also raised its projections for full-year 2026 local currency sales and adjusted EPS growth. MTD’s limited exposure to the volatile Middle East, the absence of any significant change in customer behavior and management’s confidence in executing its growth and productivity initiatives may have also supported the outlook.
Alongside this, Mettler-Toledo’s focus on capturing growth opportunities through its Spinnaker sales and marketing excellence program, as well as customer investment trends in automation, digitalization and onshoring, may have supported performance. Several recent acquisitions may have also contributed.
Mettler-Toledo International, Inc. Price and EPS Surprise
Mettler-Toledo International, Inc. price-eps-surprise | Mettler-Toledo International, Inc. Quote
Across product categories, Lab results likely benefited from improving trends across the biopharma customer base, along with robust performance in Process Analytics and bioproduction. Laboratory balances and analytical instruments may have gained from several innovations introduced in recent years, the LabX software platform and growing demand from segments such as semiconductors, advanced materials and batteries.
Industrial results in the third quarter of 2026 are likely to be driven by demand for solutions that enable automation. Strength across markets such as biopharma, food manufacturing, semiconductors and new energy may have continued. Product Inspection sales may have picked up following modest organic growth in the previous quarter, which was due to the timing of customer projects. Food Retail may have also made a favorable contribution to overall sales.
From a geographic standpoint, Mettler-Toledo likely continued to see momentum in most Lab product categories, Core Industrial Automation Solutions and Product Inspection in the Americas. Europe may have recorded growth across most of the business, with Core Industrial and Food Retail showing particular strength. Asia/Rest of the World likely continued to deliver broad-based growth across the portfolio and most major markets.
MTD’s markets outside China likely continued to deliver strong growth. Emerging markets, including India, Southeast Asia, Eastern Europe and Latin America, may have remained important contributors, supported by growth opportunities and investments in nearshoring. These regions have been a key part of the company’s long-term growth strategy and are expected to offer further opportunities as they mature.
In Mexico, the company continued to develop local assembly and manufacturing capabilities to address local market needs and enhance its competitive position. Combined, all these developments are expected to have positively impacted Mettler-Toledo’s third-quarter 2026 results.
What Our Model Unveils for MTD
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Mettler-Toledo has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #2 at present. The company is slated to release first-quarter fiscal 2027 results on Nov. 5.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.66% and a Zacks Rank #2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Nov. 4.
COR’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 0.76%. The Zacks Consensus Estimate for fourth-quarter EPS implies a jump of 18.5% from the year-ago quarter’s figure.